Vivodyne targets AI drug discovery’s human-data gap
Biotech startup Vivodyne says AI drug-discovery systems lack enough data from living human tissue. Its HIVE platform consists of modular robotic laboratories that can grow 20 types of human tissue, administer treatments autonomously and monitor the results. CEO and co-founder Andrei Georgescu says this could produce causal biological data, rather than observations limited to animals, individual cells or proteins.